We thank the following people for substantial contributions to data acquisition: Drs H. Narita, Y. Nakato, S. Nakagawa, Y. Shimizu, T. Inoue, T. Saito, K. Kitagawa, Y. Fujii, S. Asakura, K. Toyoshima, R. Kameyama, Y. Wakatsuki, Y. Mizukami, Y. Hayashishita, and T. Tanaka of the Hokkaido University Graduate School of Medicine Department of Psychiatry (Sapporo, Japan); Drs S. Ikezawa, N. Kuroki, M. Ohmori, and K. Nakagome of the National Center of Neurology and Psychiatry Department of Psychiatry (Kodaira, Japan); Drs H. Muraoka, T. Kohno, K. Takahashi, and J. Ishigooka of the Tokyo Women's Medical University Department of Psychiatry (Tokyo, Japan); Drs H. Watanabe and M. Iyo of the Chiba University Department of Psychiatry (Chiba, Japan); Dr S. Miyamoto of the St. Marianna University School of Medicine Department of Psychiatry (Kawasaki, Japan); Dr K. Hatta of the Juntendo University Nerima Hospital Department of Psychiatry (Tokyo, Japan); Drs S. Ozaki and M. Okumura of the Toshima Hospital Department of Psychiatry (Tokyo, Japan); Drs T. Kikuchi and K. Watanabe of the Kyorin University Department of Psychiatry (Mitaka, Japan); Drs H. Yoshino, S. Ueda, K. Ikeshita, Y. Nakanishi, and T. Kishimoto of the Nara Medical University Department of Psychiatry (Nara, Japan); Drs Y. Koshikawa and T. Kinoshita of the Kansai Medical University Department of Neuropsychiatry (Moriguchi, Japan); Drs S. Watabe, H. Kubo, N. Kameoka, T. Tominaga, and T. Ohmori of the Tokushima University Department of Psychiatry (Tokushima, Japan); Drs K. Kawabe, N. Sonobe, Y. Miyama, H. Shimizu and S. Ueno of the Ehime University Department of Psychiatry (Matsuyama, Japan); Drs A. Kozuki, R. Yoshimura, A. Sugita and H. Hori of the University of Occupational and Environmental Health Department of Psychiatry (Kitakyusyu, Japan); Dr T. Ueno of the Hizen Psychiatric Center (Kanzaki, Japan); Drs Y. Yada, K. Bessho, T. Horikoshi, Y. Mitsui, H. Itakura, Y. Kokoroishi, K. Sato, M. Fujiwara, M. Chida, R. Sou, M. Takase, K. Makino, Y. Kishi, T. Sunami, S. Ikeda, T. Kohno, and T. Miyake of the Okayama Psychiatric Medical Center (Okayama, Japan); Dr K. Suzuki of the Aomori Prefectural Central Hospital Department of Psychiatry (Aomori, Japan); Drs H. Tanii and M. Okada of the Mie University Department of Psychiatry (Tsu, Japan); Drs T. Hirooka and H. Miyaoka of the Kitazato University East Hospital Department of Psychiatry (Sagamihara, Japan); Drs K. Fujita, I. Yasue, S. Tanaka, M. Hattori, A. Okuda, R. Suzuki, K. Miyahara, M. Yonehara, R. Tsuji, G. Cho, K. Okada, N. Kimura, M. Takagi, T. Mekata, M. Hirano, and S. Takeichi of the Okehazama Hospital (Toyoake, Japan); Drs R. Matsubara, Y. Usukubo, R. Nozawa, and T. Fujie of the Sapporo Hanazono Hospital (Sapporo, Japan); Drs S. Iizuka, M. Sato, T. Isoyama, C. Ikeda, A. Mikami, and Y. Hyakkan of the Hakodate Watanabe Hospital (Hakodate, Japan); Drs N. Okamoto, Y. Niwa, and T. Suzuki of the Sapporo Suzuki Hospital (Sapporo, Japan); Dr K. Nakajima of the Yakumo General Hospital Department of Psychiatry (Yakumo, Japan); Dr S. Tsuchida of the Kutchan-Kosei General Hospital Department of Psychiatry (Kutchan, Japan); Drs Y. Kamikawa and N. Morita of the Kei-ai Hospital (Noboribetsu, Japan); Dr T. Takeuchi of the Tomakomai Midorigaoka Hospital (Tomakomai, Japan); Drs H. Takeshige and T. Maeda of the Hokkaido Koyogaoka Hospital (Abashiri, Japan); Drs T. Egashira, M. Oka, and H. Umezu of the Wakkanai City Hospital Department of Psychiatry (Wakkanai, Japan); Drs A. Ito and A. Mikami of the Muroran City General Hospital Department of Psychiatry (Muroran, Japan); Drs S. Miyano and H. Sawayama of the Teine Hospital (Sapporo, Japan); Drs T. Ishikane, M. Kohsaka, and H. Mieda of the Ishikane Hospital (Sapporo, Japan); Dr T. Hayashishita of the Hayashishita Hospital (Sapporo, Japan); Dr T. Komiyama of the Iida Hospital (Iida, Japan); Drs Y. Oyanagi, H. Honma, M. Okumura, Y. Hosokawa, Y. Umemoto, and T. Horinouchi of the Obihiro National Hospital Department of Neuropsychiatry (Obihiro, Japan); Dr I. Suzuki of the Sapporo Kokoronomori Clinic (Sapporo, Japan); Dr T. Matsuyama of the Okamoto Hospital (Sapporo, Japan); Dr Y. Maki of the Maki Hospital (Iwamizawa, Japan); and Drs T. Tao and J. Watanabe of the Oyachi Hospital (Sapporo, Japan). The following project staff from the Hokkaido University Hospital Clinical Research and Medical Innovation Center provided outstanding support for this project: T. Miyakoshi, A. Hirai, S. Tanno, C. Nishimura, and C. Asano, who assisted with database management, and T. Amano and K. Ono, who assisted with statistical analysis. Editage (www.editage.jp) assisted with English-language editing.
1Laursen, TM, Wahlbeck, K, Haellgren, J, Westman, J, Oesby, U, Alinaghizadeh, H, et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One 2013; 8: e67133.
2Ifteni, P, Correll, CU, Burtea, V, Kane, JM, Manu, P. Sudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatients. Schizophr Res 2014; 155: 72–6.
3Sweeting, J, Duflou, J, Semsarian, C. Postmortem analysis of cardiovascular deaths in schizophrenia: a 10-year review. Schizophr Res 2013; 150: 398–403.
4Stubbs, B, Vancampfort, D, De Hert, M, Mitchell, AJ. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systemic review and comparative meta-analysis. Acta Psychiatr Scand 2015; 132: 144–57.
5Vancompfort, D, Mitchell, AJ, De Hert, M, Sienaert, P, Probst, M, Buys, R, et al. Prevalence and predictors of type 2 diabetes mellitus in people with bipolar disorder: a systemic review and meta-analysis. J Clin Psychiatry 2015; 76: 1490–9.
6Sarwar, N, Gao, P, Seshasai, SR, Gobin, R, Kaptoge, S, Di Angelantonio, E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215–22.
7Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31–41.
8Graham, KA, Cho, H, Brownley, KA, Harp, JB. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr Res 2008; 101: 287–94.
9Newcomer, JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004; 65: 36–46.
10Kusumi, I, Ito, K, Honda, M, Hayashishita, T, Uemura, K, Hashimoto, N, et al. Screening for diabetes using Japanese monitoring guidance in schizophrenia patients treated with second-generation antipsychotics: a cross-sectional study using baseline data. Psychiatry Clin Neurosci 2011; 65: 349–55.
11Okumura, Y, Ito, H, Kobayashi, M, Miyahara, K, Matsumoto, Y, Hirakawa, J. Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study. Schizophr Res 2010; 119: 145–52.
12Van Winkel, R, De Hert, M, Van Eyck, D, Hanssens, L, Wampers, M, Scheen, A, et al. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening method. J Clin Psychiatry 2006; 67: 1493–500.
13de Leon, J, Diaz, FJ. Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. Schizophr Res 2007; 96: 185–97.
14Meyer, JM, Davis, VG, Goff, DC, McEvoy, JP, Nasrallah, HA, Davis, SM, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophr Res 2008; 101: 273–86.
15Kusumi, I, Ito, K, Uemura, K, Honda, M, Hayashishita, T, Miyamoto, K, et al. Screening for diabetes using monitoring guidance in schizophrenia patients treated with second-generation antipsychortics: a 1-year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1922–6.
16Cohn, TA, Sernyak, MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006; 51: 492–501.
17American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65: 267–72.
18World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
19Cox, DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol 1972; 34: 187–220.
20Henry, P, Thomas, F, Benetos, A, Guize, L. Impaired fasting glucose, blood pressure and cardiovascular disease mortality. Hypertension 2002; 40: 458–63.
21Iimura, O. Insulin resistance and hypertension in Japanese. Hypertens Res 1996; 19: S1–S8.
22Janghorbani, M, Amini, M. Progression from optimal blood glucose and pre-diabetes to type-2 diabetes in a high risk population with or without hypertension in Isfahan, Iran. Diabetes Res Clin Pract 2015; 108: 414–22.
23Onat, A, Yazici, M, Can, G, Kaya, Z, Bulur, S, Hergenc, G. Predictive value of prehypertension for metabolic syndrome, diabetes, and coronary heart disease among Turks. Am J Hypertens 2008; 21: 890–5.
24Gress, TW, Nieto, FJ, Shahar, E, Wofford, MR, Brancati, FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342: 905–12.
25Cheung, BMY, Li, C. Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep 2012; 14: 160–6.
27Yoshiike, N, Nishi, N, Matsushima, S, Ito, C, Ikeda, Y, Kashihara, H, et al. Relationship between severity of obesity based on body mass Index and risk factors of diabetes, hypertension and hyperlipidemia: a multisite, collaborative, epidemiological study [in Japanese]. Obesity Res 2000; 6: 4–17.